Gene info: ID 675

Gene: BRCA2

GENE ID: 675

Description: BRCA2, DNA repair associated

Gene type: protein-coding

Location: 13q13.1

dbXrefs: Ensembl:ENSG00000139618 MIM:600185 Vega:OTTHUMG00000017411 UniprotKB:P51587

RefSeq: NG_012772.3

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: ND|AD

# Publications: 56

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 7.253e-1 (AD) 6.675e-1 (ND)

DNA Methylation

Probe	Locus(GRCh37)	Gene	Region	p-val	Trait	PubMed ID
cg06935361	chr13:32964454	BRCA2		2.000e-8	Smoking	27651444
cg06935361	chr13:32964454	BRCA2		2.110e-14	Smoking	28686328

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
IL15	0.799
DDX60L	0.767
DDX58	0.738
SP140	0.736
CD80	0.732
CCL8	0.724
KRT75	0.721
CYP19A1	0.716
SAMD9	0.704
ETV7	0.702

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
WNT7A	-0.295
C19orf73	-0.294
ASPDH	-0.27
ADRA2C	-0.259
NANOS3	-0.258
SCRT1	-0.254
OLIG1	-0.252
SFTPC	-0.249
NEU4	-0.248
ATP2C2	-0.246

There is no DrugBank record for this gene !

ID	Drug Name	Action	PubMed
C028474	1,4-bis(2-(3,5-dichloropyridyloxy))benzene	"[1,4-bis(2-(3,5-dichloropyridyloxy))benzene co-treated with Pregnenolone Carbonitrile] results in increased expression of BRCA2 mRNA"	23626729
C029790	2,2',3',4,4',5-hexachlorobiphenyl	"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BRCA2 mRNA"	25510870
C029790	2,2',3',4,4',5-hexachlorobiphenyl	"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BRCA2 protein"	25510870
C029497	2,3-bis(3'-hydroxybenzyl)butyrolactone	"[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BRCA2 mRNA"	19167446
C081766	2,4,4'-trichlorobiphenyl	"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BRCA2 mRNA"	25510870
C081766	2,4,4'-trichlorobiphenyl	"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BRCA2 protein"	25510870
C014024	2,4,5,2',4',5'-hexachlorobiphenyl	"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BRCA2 mRNA"	25510870
C014024	2,4,5,2',4',5'-hexachlorobiphenyl	"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BRCA2 protein"	25510870
C009828	2,4,5,2',5'-pentachlorobiphenyl	"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BRCA2 mRNA"	25510870
C009828	2,4,5,2',5'-pentachlorobiphenyl	"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BRCA2 protein"	25510870
C009407	2,5,2',5'-tetrachlorobiphenyl	"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BRCA2 mRNA"	25510870
C009407	2,5,2',5'-tetrachlorobiphenyl	"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BRCA2 protein"	25510870
C584017	2-pyrone	BRCA2 protein affects the susceptibility to 2-pyrone	23867916
C471109	4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline	"4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline results in decreased expression of BRCA2 mRNA"	19934314
D000082	Acetaminophen	Acetaminophen results in increased expression of BRCA2 mRNA	22230336
D016604	Aflatoxin B1	Aflatoxin B1 affects the expression of BRCA2 protein	20106945
D016604	Aflatoxin B1	Aflatoxin B1 results in increased expression of BRCA2 mRNA	19770486
D016604	Aflatoxin B1	Aflatoxin B1 results in increased expression of BRCA2 mRNA	23630614
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of BRCA2 mRNA	16483693
D018501	Antirheumatic Agents	Antirheumatic Agents results in decreased expression of BRCA2 mRNA	24449571
C006632	arsenic trioxide	[arsenic trioxide co-treated with Bortezomib] results in increased expression of BRCA2 mRNA	25913414
C006632	arsenic trioxide	arsenic trioxide results in decreased expression of BRCA2 mRNA	20471514
D001280	Atrazine	Atrazine results in increased expression of BRCA2 mRNA	23358194
D001379	Azathioprine	Azathioprine results in decreased expression of BRCA2 mRNA	22623647
D001554	Benzene	Benzene affects the expression of BRCA2 mRNA	16188086
D001554	Benzene	BRCA2 gene SNP results in increased susceptibility to Benzene	16728435
D053119	Benzophenanthridines	Benzophenanthridines analog results in decreased expression of BRCA2 mRNA	23117580
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of BRCA2 mRNA	28461126
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of BRCA2 mRNA	20504355\|2222880
D015123	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of BRCA2 mRNA"	20382639
D004958	Estradiol	Estradiol results in increased expression of BRCA2 mRNA	19167446
C006780	bisphenol A	bisphenol A results in increased expression of BRCA2 mRNA	22576693
C006780	bisphenol A	bisphenol A results in increased expression of BRCA2 protein	25933419
C006780	bisphenol A	MYC protein promotes the reaction [bisphenol A results in increased expression of BRCA2 protein]	25933419
C006780	bisphenol A	bisphenol A affects the expression of BRCA2 mRNA	21786754
C006780	bisphenol A	bisphenol A affects the expression of BRCA2 mRNA	25181051
C006780	bisphenol A	bisphenol A results in increased methylation of BRCA2 gene	28505145
D000069286	Bortezomib	[arsenic trioxide co-treated with Bortezomib] results in increased expression of BRCA2 mRNA	25913414
D000069286	Bortezomib	Bortezomib results in decreased expression of BRCA2 mRNA	21917757
C018475	butyraldehyde	butyraldehyde results in decreased expression of BRCA2 mRNA	26079696
C584509	C646 compound	C646 compound results in decreased expression of BRCA2 mRNA	23698071
D019256	Cadmium Chloride	Cadmium Chloride results in increased expression of BRCA2 mRNA	12160620\|2647268
D019256	Cadmium Chloride	Cadmium Chloride results in decreased expression of BRCA2 mRNA	11958953
D019256	Cadmium Chloride	MT1 affects the reaction [Cadmium Chloride results in decreased expression of BRCA2 mRNA]	11958953
D019256	Cadmium Chloride	MT2 affects the reaction [Cadmium Chloride results in decreased expression of BRCA2 mRNA]	11958953
D019256	Cadmium Chloride	Cadmium Chloride results in increased methylation of BRCA2 promoter	22457795
D002166	Camptothecin	Camptothecin results in decreased expression of BRCA2 mRNA	10344722
D020111	Chlorodiphenyl (54% Chlorine)	Chlorodiphenyl (54% Chlorine) results in decreased expression of BRCA2 mRNA	23650126
D002794	Choline	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of BRCA2 gene	20938992
C074702	chromium hexavalent ion	chromium hexavalent ion affects the localization of BRCA2 protein	27449664
C074702	chromium hexavalent ion	chromium hexavalent ion affects the expression of BRCA2 mRNA	28472532
D003375	Coumestrol	"[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BRCA2 mRNA"	19167446
D003375	Coumestrol	[Coumestrol co-treated with resveratrol] results in increased expression of BRCA2 mRNA	19167446
D003375	Coumestrol	Coumestrol results in increased expression of BRCA2 mRNA	19167446
C408982	CPG-oligonucleotide	CPG-oligonucleotide results in decreased expression of BRCA2 mRNA	21878529
D003513	Cycloheximide	Cycloheximide inhibits the reaction [Nitrogen Mustard Compounds results in decreased expression of BRCA2 mRNA]	10344722
D016572	Cyclosporine	Cyclosporine results in decreased expression of BRCA2 mRNA	20106945\|2163298
C089595	cylindrospermopsin	cylindrospermopsin results in decreased expression of BRCA2 mRNA	23726867
D003561	Cytarabine	Cytarabine results in increased expression of BRCA2 mRNA	19194470
D000069439	Dasatinib	Dasatinib results in decreased expression of BRCA2 mRNA	20579391
C114768	decamethylcyclopentasiloxane	decamethylcyclopentasiloxane results in decreased expression of BRCA2 mRNA	27601420
D003703	Demecolcine	Demecolcine results in decreased expression of BRCA2 mRNA	23649840
D003907	Dexamethasone	Dexamethasone inhibits the reaction [RX3 gene mutant form affects the expression of BRCA2 mRNA]	27941970
C023614	dibenzofuran	dibenzofuran analog results in decreased expression of BRCA2 mRNA	20566336
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in decreased expression of BRCA2 mRNA	17361019\|2126653
D002945	Cisplatin	BRCA2 protein results in decreased susceptibility to Cisplatin	21385444
D002945	Cisplatin	BRCA2 results in decreased susceptibility to Cisplatin	21633166
D002945	Cisplatin	Cisplatin results in increased expression of BRCA2 mRNA	27594783
D004026	Dieldrin	Dieldrin results in decreased expression of BRCA2 mRNA	28385952
D004052	Diethylnitrosamine	Diethylnitrosamine results in increased expression of BRCA2 mRNA	17854601
D004052	Diethylnitrosamine	RB1 protein inhibits the reaction [Diethylnitrosamine results in increased expression of BRCA2 mRNA]	17854601
D002117	Calcitriol	Calcitriol results in decreased expression of BRCA2 mRNA	21592394
D002117	Calcitriol	[Testosterone co-treated with Calcitriol] results in decreased expression of BRCA2 mRNA	21592394
D004317	Doxorubicin	Doxorubicin results in decreased expression of BRCA2 mRNA	10344722
D004317	Doxorubicin	Doxorubicin results in increased expression of BRCA2 mRNA	22712078
D004317	Doxorubicin	Lovastatin inhibits the reaction [Doxorubicin results in increased expression of BRCA2 mRNA]	22712078
D004317	Doxorubicin	Doxorubicin results in increased oxidation of BRCA2 protein	28818578
C045651	epigallocatechin gallate	[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BRCA2 mRNA	22079256
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in increased expression of BRCA2 mRNA	17942748
D004997	Ethinyl Estradiol	[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of BRCA2 mRNA	17942748
D005492	Folic Acid	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of BRCA2 gene	20938992
D005557	Formaldehyde	BRCA2 gene mutant form results in increased susceptibility to Formaldehyde	18056434
C039281	furan	furan results in increased expression of BRCA2 mRNA	20562052\|2207923
D019833	Genistein	Genistein results in increased expression of BRCA2 mRNA	16434996
D019833	Genistein	Genistein results in increased expression of BRCA2 protein	16434996
D019833	Genistein	[indole-3-carbinol co-treated with Genistein] results in increased expression of BRCA2 protein	16434996
D006046	Gold	[Polyethyleneimine binds to Gold] which results in decreased expression of BRCA2 mRNA	28433809
C024035	hexamethylcyclotrisiloxane	hexamethylcyclotrisiloxane results in decreased expression of BRCA2 mRNA	27601420
D017313	Fenretinide	Fenretinide results in decreased expression of BRCA2 mRNA	16570282
C056493	imiquimod	imiquimod results in decreased expression of BRCA2 mRNA	21878529
C016517	indole-3-carbinol	[indole-3-carbinol co-treated with Genistein] results in increased expression of BRCA2 protein	16434996
C016517	indole-3-carbinol	indole-3-carbinol results in increased expression of BRCA2 mRNA	16434996
C016517	indole-3-carbinol	indole-3-carbinol results in increased expression of BRCA2 protein	16434996
C016517	indole-3-carbinol	indole-3-carbinol affects the expression of BRCA2 mRNA	21396975
D015759	Ionomycin	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of BRCA2 mRNA	25613284
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in decreased expression of BRCA2 mRNA	25961927
C002385	linsidomine	linsidomine results in increased oxidation of BRCA2 protein	28086193
D008095	Lithocholic Acid	BRCA2 protein results in decreased susceptibility to Lithocholic Acid	20028873
D008095	Lithocholic Acid	BRCA2 protein results in decreased susceptibility to Lithocholic Acid	20028873
D008148	Lovastatin	Lovastatin inhibits the reaction [Doxorubicin results in increased expression of BRCA2 mRNA]	22712078
D008154	Lucanthone	Lucanthone results in decreased expression of BRCA2 mRNA	21148553
D058185	Magnetite Nanoparticles	[Succimer co-treated with Magnetite Nanoparticles] results in increased expression of BRCA2 mRNA	26378955
D008715	Methionine	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of BRCA2 gene	20938992
C005223	methyleugenol	methyleugenol results in decreased expression of BRCA2 mRNA	26011634
C004925	methylmercuric chloride	methylmercuric chloride results in decreased expression of BRCA2 mRNA	28001369
D008741	Methyl Methanesulfonate	Methyl Methanesulfonate results in increased expression of BRCA2 mRNA	23649840
D008769	Methylnitronitrosoguanidine	Methylnitronitrosoguanidine results in increased expression of BRCA2 mRNA	12634122
C008493	methylselenic acid	methylselenic acid results in increased expression of BRCA2 mRNA	12517777
D015741	Metribolone	Metribolone results in increased expression of BRCA2 mRNA	17010196
D009151	Mustard Gas	BRCA2 protein inhibits the reaction [Mustard Gas affects the localization of RAD51 protein]	20435105
D009151	Mustard Gas	BRCA2 protein results in decreased susceptibility to Mustard Gas	20435105
D009151	Mustard Gas	BRCA2 results in decreased susceptibility to Mustard Gas	22119920
D009151	Mustard Gas	BRCA2 protein inhibits the reaction [Mustard Gas affects the localization of RAD51 protein]	20435105
D009151	Mustard Gas	BRCA2 protein inhibits the reaction [Mustard Gas results in increased cleavage of CASP7 protein]	20435105
D009151	Mustard Gas	BRCA2 protein inhibits the reaction [Mustard Gas results in increased cleavage of CASP9 protein]	20435105
D009151	Mustard Gas	BRCA2 protein inhibits the reaction [Mustard Gas results in increased cleavage of PARP1 protein]	20435105
D009151	Mustard Gas	BRCA2 protein results in decreased susceptibility to Mustard Gas	20435105
D037742	Nanotubes, Carbon	"Nanotubes, Carbon analog results in increased expression of BRCA2 mRNA"	25554681
D009588	Nitrogen Mustard Compounds	Cycloheximide inhibits the reaction [Nitrogen Mustard Compounds results in decreased expression of BRCA2 mRNA]	10344722
D009588	Nitrogen Mustard Compounds	Nitrogen Mustard Compounds results in decreased expression of BRCA2 mRNA	10344722
D009588	Nitrogen Mustard Compounds	Nitrogen Mustard Compounds results in increased expression of BRCA2 mRNA	27342729
C024064	octamethylcyclotetrasiloxane	octamethylcyclotetrasiloxane results in decreased expression of BRCA2 mRNA	27601420
C531550	olaparib	BRCA2 affects the susceptibility to olaparib	21633166
D010100	Oxygen	Oxygen deficiency results in decreased expression of BRCA2 mRNA	26516004
D010100	Oxygen	Oxygen deficiency results in increased expression of BRCA2 mRNA	26476374
D010100	Oxygen	Quercetin inhibits the reaction [Oxygen deficiency results in increased expression of BRCA2 mRNA]	26476374
C410127	PCB 180	"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BRCA2 mRNA"	25510870
C410127	PCB 180	"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BRCA2 protein"	25510870
C058305	phenethyl isothiocyanate	phenethyl isothiocyanate results in decreased expression of BRCA2 mRNA	26678675
D010634	Phenobarbital	Phenobarbital affects the expression of BRCA2 mRNA	19136022
C006253	pirinixic acid	pirinixic acid affects the expression of BRCA2 mRNA	19136022
C006253	pirinixic acid	pirinixic acid results in increased expression of BRCA2 mRNA	23811191
D010936	Plant Extracts	Plant Extracts results in increased expression of BRCA2 mRNA	23557933
D011094	Polyethyleneimine	[Polyethyleneimine binds to Gold] which results in decreased expression of BRCA2 mRNA	28433809
D059808	Polyphenols	Polyphenols results in decreased expression of BRCA2 mRNA	16293270
C027373	potassium chromate(VI)	[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BRCA2 mRNA	22079256
C027373	potassium chromate(VI)	potassium chromate(VI) results in decreased expression of BRCA2 mRNA	22079256
D011192	Potassium Dichromate	Potassium Dichromate results in decreased expression of BRCA2 mRNA	23608068
D011192	Potassium Dichromate	Thioctic Acid inhibits the reaction [Potassium Dichromate results in decreased expression of BRCA2 mRNA]	23608068
D011285	Pregnenolone Carbonitrile	"[1,4-bis(2-(3,5-dichloropyridyloxy))benzene co-treated with Pregnenolone Carbonitrile] results in increased expression of BRCA2 mRNA"	23626729
D011374	Progesterone	Progesterone results in decreased expression of BRCA2 mRNA	19690047
D011398	Promethazine	Promethazine results in decreased expression of BRCA2 mRNA	26011634
D011794	Quercetin	Quercetin results in increased expression of BRCA2 mRNA	15309432
D011794	Quercetin	Quercetin results in decreased expression of BRCA2 mRNA	25862958
D011794	Quercetin	Quercetin inhibits the reaction [Oxygen deficiency results in increased expression of BRCA2 mRNA]	26476374
C059514	resveratrol	[Coumestrol co-treated with resveratrol] results in increased expression of BRCA2 mRNA	19167446
C059514	resveratrol	resveratrol results in decreased expression of BRCA2 mRNA	25667456
C059514	resveratrol	resveratrol results in increased expression of BRCA2 mRNA	15149879
C059514	resveratrol	resveratrol affects the expression of BRCA2 mRNA	15748624
D012402	Rotenone	Rotenone results in increased expression of BRCA2 mRNA	18191903
C017947	sodium arsenite	sodium arsenite results in decreased expression of BRCA2 mRNA	24176670
C017947	sodium arsenite	sodium arsenite results in increased expression of BRCA2 mRNA	12760830
C017947	sodium arsenite	sodium arsenite affects the expression of BRCA2 mRNA	16507464
D018038	Sodium Selenite	Sodium Selenite results in decreased expression of BRCA2 mRNA	10344722
D004113	Succimer	[Succimer co-treated with Magnetite Nanoparticles] results in increased expression of BRCA2 mRNA	26378955
C061133	tamibarotene	tamibarotene affects the expression of BRCA2 mRNA	15498508
C061133	tamibarotene	tamibarotene results in decreased expression of BRCA2 mRNA	15498508
C047246	temozolomide	BRCA2 protein results in decreased susceptibility to temozolomide	20028873
C047246	temozolomide	BRCA2 protein results in decreased susceptibility to temozolomide	20028873
D013739	Testosterone	[Testosterone co-treated with Calcitriol] results in decreased expression of BRCA2 mRNA	21592394
D013739	Testosterone	Testosterone results in decreased expression of BRCA2 mRNA	21592394
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of BRCA2 mRNA	22574217
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of BRCA2 mRNA	21570461
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of BRCA2 mRNA	17942748
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of BRCA2 mRNA	17942748
D013755	Tetradecanoylphorbol Acetate	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of BRCA2 mRNA	25613284
D019284	Thapsigargin	Thapsigargin results in increased expression of BRCA2 mRNA	16434996
D019284	Thapsigargin	Thapsigargin results in increased expression of BRCA2 protein	16434996
D013849	Thimerosal	Thimerosal results in increased expression of BRCA2 mRNA	27188386
D008063	Thioctic Acid	Thioctic Acid inhibits the reaction [Potassium Dichromate results in decreased expression of BRCA2 mRNA]	23608068
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in increased methylation of BRCA2 gene	26756918
D014212	Tretinoin	Tretinoin affects the expression of BRCA2 mRNA	15498508
D014212	Tretinoin	Tretinoin results in decreased expression of BRCA2 mRNA	15498508
C012589	trichostatin A	trichostatin A results in decreased expression of BRCA2 mRNA	23770000
C015559	trimellitic anhydride	trimellitic anhydride results in increased expression of BRCA2 mRNA	19042947
C016805	tris(1,3-dichloro-2-propyl)phosphate	"tris(1,3-dichloro-2-propyl)phosphate results in decreased expression of BRCA2 mRNA"	26179874
D014415	Tunicamycin	Tunicamycin results in increased expression of BRCA2 protein	16434996
D014635	Valproic Acid	Valproic Acid affects the expression of BRCA2 mRNA	25979313
D014635	Valproic Acid	Valproic Acid results in decreased expression of BRCA2 mRNA	23179753\|2718838
D014635	Valproic Acid	Valproic Acid results in decreased expression of BRCA2 mRNA	24913804
D014635	Valproic Acid	Valproic Acid results in increased expression of BRCA2 mRNA	24913804
D001335	Vehicle Emissions	Vehicle Emissions results in decreased methylation of BRCA2 gene	25560391
C521013	veliparib	BRCA2 affects the susceptibility to veliparib	21633166
C111237	vorinostat	vorinostat results in increased expression of BRCA2 mRNA	27188386
D015032	Zinc	Zinc deficiency results in decreased expression of BRCA2 mRNA	18356318
C023616	zinc chromate	zinc chromate affects the localization of BRCA2 protein	27449664
C088658	zoledronic acid	zoledronic acid results in increased expression of BRCA2 mRNA	20977926

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0002020	protease binding	-	IBA	21873635
GO:0002020	protease binding	-	IPI	15314155
GO:0003697	single-stranded DNA binding	-	IBA	21873635
GO:0003697	single-stranded DNA binding	-	IDA	20729832
GO:0004402	histone acetyltransferase activity	NOT	IBA	21873635
GO:0004402	histone acetyltransferase activity	NOT	IDA	9824164
GO:0005515	protein binding	-	IBA	21873635
GO:0005515	protein binding	-	IPI	9560268 9774970 10373512 10551859 11597317 12242698 12442171 15115758 15800615 15930293 15967112 16099937 16205630 16275750 17420451 17515903 17515904 17541404 18212739 18264088 19303847 19369211 19423707 19609323 19628690 20421506 20729832 20729859 21399666 21601571 21719596 22116401 22193777 22293751 24013206 24141787 24485656 25282148 25585578 26649820
GO:0008022	protein C-terminus binding	-	IBA	21873635
GO:0008022	protein C-terminus binding	-	IDA	9774970
GO:0010484	H3 histone acetyltransferase activity	-	IDA	9619837
GO:0010485	H4 histone acetyltransferase activity	-	IDA	9619837
GO:0042802	identical protein binding	-	IBA	21873635
GO:0042802	identical protein binding	-	IPI	21601571 25282148
GO:0043015	gamma-tubulin binding	-	IBA	21873635
GO:0043015	gamma-tubulin binding	-	IPI	17286961

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000281	mitotic cytokinesis	-	IDA	17286961
GO:0000722	telomere maintenance via recombination	-	IBA	21873635
GO:0000722	telomere maintenance via recombination	-	IEA	-
GO:0000724	double-strand break repair via homologous recombination	-	IBA	21873635
GO:0000724	double-strand break repair via homologous recombination	-	IDA	20729832
GO:0000724	double-strand break repair via homologous recombination	-	IMP	21719596
GO:0001556	oocyte maturation	-	IBA	21873635
GO:0001556	oocyte maturation	-	IEA	-
GO:0001833	inner cell mass cell proliferation	-	IBA	21873635
GO:0001833	inner cell mass cell proliferation	-	IEA	-
GO:0006289	nucleotide-excision repair	-	IBA	21873635
GO:0006289	nucleotide-excision repair	-	IMP	16845393
GO:0006302	double-strand break repair	-	IMP	16845393
GO:0006355	regulation of transcription, DNA-templated	-	IBA	21873635
GO:0006978	DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	-	IBA	21873635
GO:0006978	DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	-	IEA	-
GO:0007141	male meiosis I	-	IBA	21873635
GO:0007141	male meiosis I	-	IEA	-
GO:0007283	spermatogenesis	-	IBA	21873635
GO:0007283	spermatogenesis	-	IEA	-
GO:0007420	brain development	-	IBA	21873635
GO:0007420	brain development	-	IEA	-
GO:0007569	cell aging	-	IEA	-
GO:0007584	response to nutrient	-	IBA	21873635
GO:0008585	female gonad development	-	IBA	21873635
GO:0008585	female gonad development	-	IEA	-
GO:0010165	response to X-ray	-	IBA	21873635
GO:0010165	response to X-ray	-	IEA	-
GO:0010225	response to UV-C	-	IBA	21873635
GO:0010225	response to UV-C	-	IEA	-
GO:0010332	response to gamma radiation	-	IBA	21873635
GO:0010332	response to gamma radiation	-	IEA	-
GO:0010778	meiotic DNA repair synthesis involved in reciprocal meiotic recombination	-	IBA	21873635
GO:0030097	hemopoiesis	-	IBA	21873635
GO:0030097	hemopoiesis	-	IEA	-
GO:0030879	mammary gland development	-	IBA	21873635
GO:0031619	homologous chromosome orientation involved in meiotic metaphase I plate congression	-	IBA	21873635
GO:0032355	response to estradiol	-	IBA	21873635
GO:0032465	regulation of cytokinesis	-	IBA	21873635
GO:0032465	regulation of cytokinesis	-	IEA	-
GO:0033600	negative regulation of mammary gland epithelial cell proliferation	-	IBA	21873635
GO:0033600	negative regulation of mammary gland epithelial cell proliferation	-	IDA	15930293
GO:0035264	multicellular organism growth	-	IBA	21873635
GO:0042127	regulation of cell proliferation	-	IBA	21873635
GO:0042771	intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	-	IBA	21873635
GO:0042771	intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	-	IEA	-
GO:0043150	DNA synthesis involved in double-strand break repair via homologous recombination	-	IBA	21873635
GO:0043966	histone H3 acetylation	-	IBA	21873635
GO:0043966	histone H3 acetylation	-	IDA	9619837
GO:0043967	histone H4 acetylation	-	IBA	21873635
GO:0043967	histone H4 acetylation	-	IDA	9619837
GO:0045893	positive regulation of transcription, DNA-templated	-	IBA	21873635
GO:0045893	positive regulation of transcription, DNA-templated	-	IDA	9126734
GO:0045931	positive regulation of mitotic cell cycle	-	IBA	21873635
GO:0045931	positive regulation of mitotic cell cycle	-	IEA	-
GO:0048478	replication fork protection	-	IBA	21873635
GO:0048478	replication fork protection	-	IEA	-
GO:0051298	centrosome duplication	-	IBA	21873635
GO:0051298	centrosome duplication	-	IMP	17286961
GO:0051598	meiotic recombination checkpoint	-	IBA	21873635
GO:0070200	establishment of protein localization to telomere	-	IBA	21873635
GO:0070200	establishment of protein localization to telomere	-	IDA	21076401
GO:1990426	mitotic recombination-dependent replication fork processing	-	IBA	21873635
GO:1990426	mitotic recombination-dependent replication fork processing	-	IMP	21076401

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000784	nuclear chromosome, telomeric region	-	IBA	21873635
GO:0000784	nuclear chromosome, telomeric region	-	IDA	21076401
GO:0000800	lateral element	-	IBA	21873635
GO:0000800	lateral element	-	IDA	9774970
GO:0005634	nucleus	-	IBA	21873635
GO:0005634	nucleus	-	IDA	9560268 9774970 17286961
GO:0005654	nucleoplasm	-	IBA	21873635
GO:0005654	nucleoplasm	-	IDA	-
GO:0005654	nucleoplasm	-	TAS	-
GO:0005813	centrosome	-	IBA	21873635
GO:0005813	centrosome	-	IDA	17286961 21276791
GO:0005829	cytosol	-	IBA	21873635
GO:0005829	cytosol	-	IDA	-
GO:0030141	secretory granule	-	IBA	21873635
GO:0030141	secretory granule	-	IDA	8589722
GO:0032991	protein-containing complex	-	IDA	9774970
GO:0033593	BRCA2-MAGE-D1 complex	-	IBA	21873635
GO:0033593	BRCA2-MAGE-D1 complex	-	IDA	15930293

KEGG ID	KEGG Term
hsa03440	Homologous recombination
hsa05200	Pathways in cancer
hsa05212	Pancreatic cancer

Reactome ID	Reactome Term	Evidence
R-HSA-1474165	Reproduction	IEA
R-HSA-1500620	Meiosis	IEA
R-HSA-1640170	Cell Cycle	IEA
R-HSA-5685942	HDR through Homologous Recombination (HRR)	TAS
R-HSA-5693532	DNA Double-Strand Break Repair	TAS
R-HSA-5693537	Resolution of D-Loop Structures	TAS
R-HSA-5693538	Homology Directed Repair	TAS
R-HSA-5693554	Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)	TAS
R-HSA-5693567	HDR through Homologous Recombination (HR) or Single Strand Annealing (SSA)	TAS
R-HSA-5693568	Resolution of D-loop Structures through Holliday Junction Intermediates	TAS
R-HSA-5693579	Homologous DNA Pairing and Strand Exchange	TAS
R-HSA-5693616	Presynaptic phase of homologous DNA pairing and strand exchange	TAS
R-HSA-73894	DNA Repair	TAS
R-HSA-912446	Meiotic recombination	IEA

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
12718618	An Epidemiological Overview of Environmental and Genetic Risk Factors of Pancreatic Cancer. (2001)	Lin Y	Asian Pac J Cancer Prev
27907901	Serum AMH levels in healthy women from BRCA1/2 mutated families: are they reduced? (2016 Nov)	van Tilborg TC	Hum Reprod
9605646	Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. (1998 May 20)	Brunet JS	J Natl Cancer Inst
9605638	Protective effect of cigarette smoking on breast cancer risk in women with BRCA1 or BRCA2 mutations??? (1998 May 20)	Baron JA	J Natl Cancer Inst
19826425	Familial association of pancreatic cancer with other malignancies in Swedish families. (2009 Nov 17)	Hiripi E	Br J Cancer
16888680	[Familial pancreatic cancer]. (2006)	Zalatnai A	Magy Onkol
27852187	Prevention of breast cancer. (2016 Nov 21)	Olver IN	Med J Aust
21368091	Comprehensive pathway-based association study of DNA repair gene variants and the risk of nasopharyngeal carcinoma. (2011 Apr 15)	Qin HD	Cancer Res
18037339	Genetic polymorphisms and micronucleus formation: a review of the literature. (2008 Mar-Apr)	Iarmarcovai G	Mutat Res
12555988	Premalignant conditions of the pancreas. (2002 Dec)	Hall Pde L	Pathology
29330845	The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers. (2018 Jun 1)	Ko KP	Int J Cancer
12214307	Evidence for a major gene influencing risk of pancreatic cancer. (2002 Aug)	Klein AP	Genet Epidemiol
22162228	Genetic susceptibility to pancreatic cancer. (2012 Jan)	Klein AP	Mol Carcinog
23748177	Risk factors for ovarian cancers with and without microsatellite instability. (2013 Jul)	Segev Y	Int J Gynecol Cancer
16162302	Treatment of familial pancreatic cancer and its precursors. (2005 Oct)	Hruban RH	Curr Treat Options Gastroenterol
12917199	Screening of homologous recombination gene polymorphisms in lung cancer patients reveals an association of the NBS1-185Gln variant and p53 gene mutations. (2003 Aug)	Medina PP	Cancer Epidemiol Biomarkers Prev
20961843	[The epidemiology of pancreatic cancer]. (2010 Oct 31)	Lakatos G	Orv Hetil
17972172	Smoking and risk of breast cancer in carriers of mutations in BRCA1 or BRCA2 aged less than 50 years. (2008 May)	-	Breast Cancer Res Treat
28871957	[Expression of BRCA2 in tumor tissues in patients with laryngeal squamous cell carcinoma and its clinical significance]. (2017 Aug)	He X	Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
21761160	Variation in breast cancer risk with mutation position, smoking, alcohol, and chest X-ray history, in the French National BRCA1/2 carrier cohort (GENEPSO). (2011 Dec)	Lecarpentier J	Breast Cancer Res Treat
27094481	Anti-Mullerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations. (2016 May)	Phillips KA	Hum Reprod
11795442	Hormonal prevention of hereditary breast cancer. (2001 Dec)	Narod SA	Ann N Y Acad Sci
15849724	Risk factors for pancreatic cancer. (2005 Jul 1)	Lowenfels AB	J Cell Biochem
15231857	Epidemiology and prevention of pancreatic cancer. (2004 May)	Lowenfels AB	Jpn J Clin Oncol
28975393	Smoking and physical inactivity increase cancer prevalence in BRCA-1 and BRCA-2 mutation carriers: results from a retrospective observational analysis. (2017 Dec)	Grill S	Arch Gynecol Obstet
23362014	Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California. (2013 May 1)	Lin WT	Cancer
18269778	Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. (2007 Dec)	Friebel TM	Clin Breast Cancer
11064350	Association of allelic imbalance at locus D13S171 (BRCA2) and p53 alterations with tumor kinetics and chromosomal instability (aneuploidy) in nonsmall cell lung carcinoma. (2000 Nov 1)	Gorgoulis VG	Cancer
25838159	Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study. (2015 Sep)	Segev Y	Fam Cancer
25532426	Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer. (2015 Feb)	Fakkert IE	Eur J Cancer
28472989	Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. (2017 May 4)	Yang M	J Hematol Oncol
28375947	Chronic Pancreatitis-Like Change in BRCA2 Mutation Carriers. (2017 May/Jun)	Mizrahi M	Pancreas
28078281	The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer. (2016)	Martinez-Useros J	Biomed Res Int
19150414	Genetic predisposition and environmental risk factors to pancreatic cancer: A review of the literature. (2009 Mar-Jun)	Landi S	Mutat Res
24755492	Risk factors for ovarian cancers with and without microsatellite instability. (2014 May)	Segev Y	Int J Gynecol Cancer
14981540	A delayed chemically induced tumorigenesis in Brca2 mutant mice. (2004 Mar 11)	Yan DH	Oncogene
11561603	Familial pancreatic cancer. (2001 Jul-Aug)	Klein AP	Cancer J
18483851	Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update. (2009 Mar)	Ginsburg O	Breast Cancer Res Treat
17912010	Cancer risk among the relatives of patients with pancreatic ductal adenocarcinoma. (2007)	Del Chiaro M	Pancreatology
17289874	Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer. (2007 Feb 1)	Lee MN	Clin Cancer Res
16541324	Diet, lifestyle and BRCA-related breast cancer risk among French-Canadians. (2006 Aug)	Nkondjock A	Breast Cancer Res Treat
22126563	Frequent germline mutation in the BRCA2 gene in esophageal squamous cell carcinoma patients from a low-risk Chinese population. (2011)	Zhong L	Asian Pac J Cancer Prev
24824314	Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. (2014 Jun)	Friebel TM	J Natl Cancer Inst
12544504	Risk factors and risk reduction of breast and ovarian cancer. (2003 Feb)	Brekelmans CT	Curr Opin Obstet Gynecol
15095307	Smoking and the risk of breast cancer among carriers of BRCA mutations. (2004 Jun 20)	Ghadirian P	Int J Cancer
26569048	Genital Cancers in Women: Ovarian Cancer. (2015 Nov)	Kuznia AL	FP Essent
26654799	Pancreatic Cancer Diagnostics and Treatment--Current State. (2015)	Krska Z	Prague Med Rep
23663450	Genetic polymorphisms of DNA double-strand break repair pathway genes and glioma susceptibility. (2013 May 10)	Zhao P	BMC Cancer
19902366	Genetic variation in DNA repair genes and prostate cancer risk: results from a population-based study. (2010 Feb)	Agalliu I	Cancer Causes Control
23213974	Etiology and oncogenesis of pancreatic carcinoma. (2012 Sep)	Dobrila-Dintinjana R	Coll Antropol
12670518	Epidemiology of pancreatic cancer: an overview. (2003)	Ghadirian P	Cancer Detect Prev
16261399	Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. (2006 Jan)	Gronwald J	Breast Cancer Res Treat
27732944	Germline mutations in Japanese familial pancreatic cancer patients. (2016 Nov 8)	Takai E	Oncotarget
28729482	BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity. (2017 Oct)	Tacconi EM	EMBO Mol Med
15040392	Epidemiology of breast cancer among BRCA mutation carriers: an overview. (2004 Mar 8)	Nkondjock A	Cancer Lett
10464641	Evaluation of genotype data in clinical risk assessment: methods and application to BRCA1, BRCA2, and N-acetyl transferase-2 genotypes in breast cancer. (1997-1998)	Rebbeck TR	Genet Test